Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma

International Journal of Cancer

Volumn 115, Issue 1, 2005, Pages 155-163

  Ferguson, Roisean E ^a   Jackson, Sharon M ^a   Stanley, Anthea J ^a   Joyce, Adrian D ^a   Harnden, Patricia ^a   Morrison, Ewan E ^a   Patel, Poulam M ^a   Phillips, Roger M ^b   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Epothilone, tubulin; Major vault protein; Multidrug resistance protein; P glycoprotein; Renal cancer

Indexed keywords

ANTIMITOTIC AGENT; EPOTHILONE B; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; KIDNEY; KIDNEY NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; PHENOTYPE; SENSITIVITY AND SPECIFICITY; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TUBULIN; UP-REGULATION; VINBLASTINE; VINCRISTINE;

EID: 20244370600     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20816     Document Type: Article

References (47)

1. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:1691-6.
2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
3. Baird RD, Kaye SB. Drug resistance reversal: are we getting closer? Eur J Cancer 2003;39:2450-61.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
5. Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988;139:862-5.
6. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993;24:156-60.
7. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5:1922-7.
8. Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 1996;156:506-11.
9. Rochlitz CF, Lobeck H, Peter S, Reuter J, Mohr B, de Kant E, Huhn D, Herrmann R. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. Cancer 1992;69:2993-8.
10. Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 1992;52:3029-34.
11. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 1995;95:2205-14.
12. Reinecke P, Schmitz M, Schneider EM, Gabbert HE, Gerharz CD. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest 2000;18:614-25.
13. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989;81:844-9.
14. Bak M Jr, Efferth T, Mickisch G, Mattern J, Volm M. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 1990;17:72-5.
15. Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 1990;144:755-9.
16. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23.
17. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
18. Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, Storkel S, Thon WF, Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999;10:1159-69.
19. Sandusky GB, Mintze KS, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002;41:65-74.
20. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 1999;456:327-31.
21. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localisation, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-94.
22. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 2004;65:230-8.
23. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a M(r) 110,000 vesicular protein in non-P-ylycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475-9.
24. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJLM, van der Valk P, Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148:877-87.
25. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, Selby PJ, Banks RE. Serological and proteomic evaluation of antibody responses in the identification of tumour antigens in renal cell carcinoma. Proteomics 2003;3:45-55.
26. Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 1997;72:1021-6.
27. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
28. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002;2:123-48.
29. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-20.
30. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987;47:943-6.
31. Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003;30:51-5.
32. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures: a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000;1470:M79-91.
33. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-7.
34. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-30.
35. Nishiyama K, Shirahama T, Yoshimura A, Sumizawa T, Furukawa T, Ichikawa-Haraguchi M, Akiyama S, Ohi Y. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993;71:3611-9.
36. Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ, Kamst E, Borst P, Baas F. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Br J Cancer 1995;72:298-306.
37. Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick RW, Skorecki KL, Warner E. Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1995;1:1611-5.
38. Gamelin E, Merlins SD, Regis JT, Mickley L, Abati A, Worrell RA, Linehan WM, Bates SE. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol 1999;162:217-24.
39. Duensing S, Dallmann I, Grosse J, Buer J, Lopez HE, Deckert M, Storkel S, Kirchner H, Poliwoda H, Atzpodien J. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994;51:309-13.
40. van Kalken CK, van der Valk P, Hadisaputro MM, Pieters R, Broxterman HJ, Kuiper CM, Scheffer GL, Veerman AJ, Meyer CJ, Scheper RJ. Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney. Ann Oncol 1991;2:55-62.
41. Hofmockel G, Bassukas ID, Wittmann A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 1997;80:11-7.
42. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-94.
43. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003;13:83-9.
44. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-7.
45. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001;61:5803-9.
46. Scheltema JM, Romijn JC, van Steenbrugge GJ, Schroder FH, Mickisch GH. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer Res 2001;21:3161-6.
47. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 2002;22:121-8.